Department of Pharmacology & Chemical Biology at the University of Pittsburgh
Wen Xie, MD, PhD
Professor and the Joseph Koslow Endowed Chair in Pharmaceutical Sciences
656 Salk Hall
Pittsburgh, PA 15213

Phone: 412-648-9941

Fax: 412-648-1664

MD, Peking University Health Science Center, 1991.
PhD (Cell Biology), University of Alabama at Birmingham, 1997.
Postdoctoral Fellow (Nuclear Hormone Receptor), Salk Institute, 1998-2002.

Research Areas
Pharmacology of Cell and Organ Systems
Signal Transduction
Photo of Wen Xie, MD, PhD

The research focus of Dr. Xie's laboratory is nuclear receptor-mediated transcriptional regulation of genes that encode drug metabolizing enzymes and drug transporters. This regulation has broad implications in drug metabolism and human diseases, such as hepatobiliary diseases, endocrine disorders, metabolic syndrome, and cancers.  Dr. Xie’s research is conducted using a combination of cell cultures and genetically engineered mice that include transgenic, knockout and humanized mice.  The nuclear receptor we are most interested of include the pregnane X receptor (PXR), constitutive androstane receptor (CAR), liver X receptor (LXR), retinoid-related orphan receptor  (ROR), and farnesoid X receptor (FXR).  Dr. Xie is the author or coauthor of over 110 journal articles and book chapters and over 120 invited lectures at conferences and universities.  Dr. Xie is the sole editor of "Nuclear Receptors in Drug Metabolism," a book published by Wiley. Dr. Xie currently serves ad hoc reviewer for the NIH and DOD Study Sections and for over 60 scientific journals. Among his achievements, Dr. Xie is the recipient of the University of Pittsburgh Chancellor’s Distinguished Research Award, the James R. Gillette International Society for the Study of Xenobiotics (ISSX) North American New Investigator Award, the American Society for Pharmacology and Experimental Therapeutics (ASPET) Division for Drug Metabolism Early Career Achievement Award, and the Joseph Koslow Endowed Chair in Pharmaceutical Sciences.

Important Publications
He J, S Nishida, M Xu, M Makishima and W Xie.  PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts.  Gastroenterology 140:2095-2106, 2011.
Ou Z, X Shi, RK Gilroy, L Kirisci, M Romkes, C Lynch, H Wang, M Xu, M Jiang, S Ren, R Gramignoli, SC Strom, M Huang and W Xie.  Regulation of the human hydroxysteroid sulfotransferase SULT2A1 by ROR alpha and ROR gamma and its potential relevance in human liver diseases.  Mol Endocrinol 2012 Dec 4 [Epub ahead of print].
Gao J, J He, X Shi, M Stefanovic-Racic, M Xu, RM O'Doherty, A Garcia-Ocana and W Xie.  Sex-specific effect of estrogen sulfotransferase (EST) on mouse models of type 2 diabetes.  Diabetes 61:1543-1551, 2012.
Saini SPS, B Zhang, Y Niu, M Jiang, J Gao, Y Zhai, JH Lee, H Uppal, H Tian, MA Tortorici, SM Poloyac, W Qin, R Venkataramanan and W Xie.  Activation of LXR increases acetaminophen clearance and prevents its toxicity in mice.  Hepatology 54:2208-2217, 2011.
Wada T, CA Ihunnah, J Gao, X Chai, S Zeng, BJ Philips, JP Rubin, KG Marra and W Xie.  Estrogen sulfotransferase inhibits adipocyte differentation.  Mol Endocrinol 25:1612-1623, 2011.

Back to Top